Related Experiment Video
Updated: May 9, 2025
06:46
Compartmentalization of Human Stem Cell-Derived Neurons within Pre-Assembled Plastic Microfluidic Chips
Published on: May 3, 2019
65.8K
Encapsulation of trabecular meshwork mesenchymal stem cell using microfluidic system for differentiation into
Sina Rahmani1,2, Samad Nadri3,4,5, Mehdi Eskandari2
1Student Research Committee, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
The International Journal of Artificial Organs
|April 29, 2025
Summary
Microfluidic encapsulation of trabecular meshwork stem cells successfully differentiated them into neural-like cells, showing potential for neurodegenerative disease therapies.
Area of Science:
- Biomedical Engineering
- Neuroscience
- Stem Cell Biology
Background:
- Neurodegenerative diseases involve progressive neuronal loss.
- Microfluidic technology offers a novel approach for stem cell encapsulation and transplantation.
- Trabecular meshwork-derived mesenchymal stem cells (TM-MSCs) are being explored for neural repair.
Purpose of the Study:
- To encapsulate and differentiate human mesenchymal stem cells (MSCs) from trabecular meshwork (TM) tissue into neural-like cells using a microfluidic platform.
- To evaluate the potential of these differentiated cells for neural repair applications.
- To assess the efficacy of the microfluidic system as a delivery vehicle for TM-MSCs.
Main Methods:
- Human TM-MSCs were cultured and differentiated using a microfluidic system fabricated by soft lithography.
- Cells were treated with a differentiation medium containing Retinoic Acid (RA), IBMX, and forskolin for 7 days.
- Quantitative PCR (qPCR) was employed to analyze the expression of neural-specific markers (Nestin and β-tubulin 3).
Main Results:
- qPCR confirmed the expression of neural-like markers (Nestin and β-tubulin 3) in differentiated TM-MSCs, both in the microfluidic system and on traditional tissue culture plates (TCPS).
- Higher expression of β-tubulin 3 was observed in cells encapsulated in 1.5% alginate compared to 1% alginate, 2% alginate, and TCPS (p < 0.0001).
- No statistically significant differences in Nestin expression were found across all tested conditions (p > 0.05).
Conclusions:
- Trabecular meshwork-derived mesenchymal stem cells (TM-MSCs) show promise as a cell source for therapeutic strategies targeting neurological disorders.
- The developed microfluidic platform is a viable delivery system for TM-MSCs in potential therapeutic interventions.
- This study highlights the potential of microfluidic-assisted stem cell differentiation for neural repair applications.
